New patient-centric solution for the management of chronic respiratory insufficiency diseases

November 16, 2012

Philips Respironics today announces the availability of the new bi-level ventilator BiPAP A401 for the management of chronic respiratory insufficiency, a condition secondary to diseases such as obesity hypoventilation syndrome, chronic obstructive pulmonary disease (COPD) and neuromuscular disease for adult and pediatric patients (above 10 kg).

Launching on World COPD Day 2012 and being showcased this week at Medica 2012, the world's largest medical trade fair, the BiPAP A40 improves the management of chronic respiratory diseases by offering a range of unique benefits that facilitate the smoothest possible transition in the patient care pathway – from initial titration to , from home therapy to long-term follow-up.

"Philips is proud to be able to provide access to new and innovative solutions that improve quality of care for respiratory patients – both in hospital and at home," comments Mats Dahlquist, general manager international, Philips Home Healthcare Solutions.

One of the key benefits of the BiPAP A40 is an innovative ventilation mode called AVAPS-AE, which helps to guide clinicians during the initial titration of therapy, while maintaining comfort and improving efficacy for the patient. This new ventilation mode automatically maintains airway patency while delivering the correct level of ventilation each user requires, whatever their body position or sleep stage. AVAPS-AE mode also helps to guide clinicians during the initial titration of therapy, while providing long term comfort and assuring therapy compliance.

In addition to the introduction of AVAPS-AE, the BiPAP A40 features a unique battery module design which provides users with an enhanced level of autonomy that increases support when traveling, or in the case of a power shortage. Furthermore, the design incorporates an intuitive user interface and data management tools that allow clinicians to remotely access and review data about a user's therapy, adjusting it as necessary. This can help to reduce therapy drop out and the associated risk of hospital re-admission.

Although many are preventable and can be effectively managed, they continue to be an important cause of morbidity, mortality and the increased health care costs worldwide. COPD is predicted to become the third leading cause of death worldwide by 2030, with 65 million people currently living with the disease across the world. "COPD is a particularly costly disease to manage, with an annual healthcare bill of more than 10 billion Euros across the EU alone."

Explore further: Miniature ventilator may help COPD patients improve mobility

More information: Wouters EFM. Economic analysis of the confronting COPD survey: an overview of results. Respir Med 2003; 97:S3-S14.
www.philips.com/BiPAP

Related Stories

Miniature ventilator may help COPD patients improve mobility

May 16, 2011

A miniature, easy-to-carry ventilation system with a simple nasal mask may help patients with chronic obstructive pulmonary disease (COPD) become more active, according to research conducted at medical centers in California ...

Recommended for you

Molecular Zika study finds possible target for tests, drugs

April 19, 2016

The molecular structure of the Zika virus as seen on x-ray crystallography revealed electrostatic differences in a key protein compared with other flaviviruses that might explain how it infects human cells, according to a ...

Zika virus may now be tied to another brain disease

April 10, 2016

The Zika virus may be associated with an autoimmune disorder that attacks the brain's myelin similar to multiple sclerosis, according to a small study that is being released today and will be presented at the American Academy ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.